Background-The vascular smooth muscle cell (VSMC) is the central cell component involved in the fibroproliferative response in atherogenesis. As the lesion advances, VSMCs migrate from the media into the subendothelial space, thereby forming fibrous plaque lesions. Platelet-derived growth factor (PDGF) has been known to be a potent chemoattractant and mitogen for SMCs, but the pathophysiological role of the 2 PDGF receptors, receptor-␣ (PDGFR-␣) and receptor-␤ (PDGFR-␤) in atherogenesis is poorly understood. To clarify this problem, we prepared antagonistic rat monoclonal antibodies, APA5 and APB5, against murine PDGFR-␣ and PDGFR-␤, respectively. Methods and Results-Apolipoprotein E-deficient mice were fed a high-fat diet containing 0.3% cholesterol from 6 weeks of age and subjected to injection with 1 mg/d IP of either antibody from 12 to 18 weeks every other day. In the mice injected with APB5, the aortic atherosclerotic lesion size and the number of intimal VSMCs were reduced by 67% and 80%, respectively, compared with the control mice injected with irrelevant rat IgG. In contrast, the mice that received APA5 showed only minimal reduction of lesion size, and a large number of VSMCs were observed in the intima. In the intima of advanced lesions, APB5 immunolabeled VSMCs, whereas APA5 could detect VSMCs mainly in the media.
A therosclerosis develops as a result of multiple inflammatory-fibroproliferative responses. 1 The fatty streak lesions, filled mainly with macrophage-derived foam cells, proceed to intermediate lesions associated with vascular smooth muscle cells (VSMCs) migrating from the media. As pathological events continue, the intermediate lesions are converted into the further advanced lesions characterized by considerable accumulation of extracellular lipid, lipidcontaining foam cells of macrophage and VSMC origin, and extracellular matrices. 2 Recently, we reported that fatty streak formation was prevented in apolipoprotein E (apoE)-deficient mice by administration of an antagonistic monoclonal antibody (mAb) against murine c-fms, the receptor for macrophage colonystimulating factor. 3 This antibody had little effect, however, on the advanced fibrous lesions associated with a larger number of VSMCs in the intima. Among various growth factors, platelet-derived growth factor (PDGF) released from activated platelets, vascular endothelial cells, VSMCs, and monocytes is an important mediator of VSMC proliferation and migration. 4 PDGF exists as a disulfide-linked dimer and is composed of 2 chains, A and B. 5 Two receptors for PDGF, called ␣ and ␤, have been identified. 6 Both receptors are transmembrane glycoproteins with intrinsic tyrosine kinase activity. 7 Binding of PDGF to the receptor induces receptor dimerization and activation of the kinase activity. The ␣-receptor (PDGFR-␣) binds both PGDF-A and -B chains, whereas the ␤-receptor (PDGFR-␤) binds only the PDGF-B chain. 8, 9 The role of the PDGFR has been described in postinjury lesions by use of anti-PDGFR-␤ antibody in the baboon. 10 It has also been reported that both types of PDGF chains and their receptors could be detected in wound-healing processes of human coronary arteries after angioplasty. 11, 12 These results suggest that PDGF and its receptors are involved in the development of intimal lesions at sites of acute vascular injury.
Thus far, gene-targeting experiments have been attempted to create knockout mice deficient for PDGF-A, 13 PDGF-B, 14 PDGFR-␣, 15 or PDGFR-␤. 16 Those mice, however, died either at the embryonic stage or several days after birth. This has made it difficult to study the significance of PDGF and its receptors in atherogenesis in vivo and left unanswered the question of whether PDGF could be involved in the natural course of atherogenesis that occurs without provocation, such as mechanical vascular injury.
To solve this problem, we administered 2 types of rat mAb, APA5 and APB5, directed against murine PDGFR-␣ and PDGFR-␤, respectively, into 12-week-old apoE-deficient mice developing advanced atherosclerotic lesions. We report that PDGFR-␣ and PDGFR-␤ have distinct roles in progression and maintenance of the advanced atherosclerotic regions associated with accumulation of VSMCs.
Methods

Mice
The apoE-deficient mice were generous gifts from Dr Edward M. Rubin (University of California at Berkeley) and were hybrid 129ola ϫ C57BL/6 mice. 17, 18 The mice were kept in a temperaturecontrolled facility on a 14 hours light/10 hours dark cycle with free access to food and water. After being weaned at 4 weeks of age, the mice were fed a normal chow diet (CMF, Oriental Yeast) until 6 weeks of age, when experiments were started.
Rat mAbs Directed Against Murine PDGFR-␣ and PDGFR-␤
APA5, a rat monoclonal anti-murine PDGFR-␣ antibody (IgG2a), was described previously. 19 Anti-murine PDGFR-␤ antibody, APB5, was prepared as follows. A cDNA fragment corresponding to the extracellular domain of murine PDGFR-␤ 20 was generated by reverse transcription-polymerase chain reaction amplification of mRNA prepared from the NIH3T3 cells. The amplified DNA fragment was inserted into CD4Rg, 21 from which the CD4 gene had been removed. The DNA construct was transfected into the COS-1 cell line. The PDGFR-␤/human IgG1 recombinant fusion protein was purified from the culture supernatant of the transfected COS-1 cells. Spleen cells from a Wistar rat immunized and boosted with this fusion protein were fused with X63.Ag8 cells, as described previously. 22 Detection of Autophosphorylated PDGFR-␤ AC01 cells, a line of VSMCs established from p53-deficient mice, were kindly provided by Dr Kazuhiro Ohmi (National Children's Research Center, Tokyo, Japan). 23 The synchronized AC01 cells were preincubated with either APA5, APB5, or irrelevant isotypematched control rat IgG and were stimulated with 100 ng/mL of PDGF-BB at 37°C for 5 minutes. The cells were lysed as described previously, 24 and the PDGFR-␤ was detected by immunoblotting with either rabbit anti-murine PDGFR-␤ polyclonal antibody, described previously 25 (generously provided by Dr L.T. Williams, Chiron Corp) or mouse anti-phosphotyrosine antibody 4G10 (Upstate Biotechnology). To detect autophosphorylated PDGFR-␤ after immunoprecipitation, the cell lysates were incubated first with rabbit anti-human PDGFR-␤ antiserum (Upstate Biotechnology) and subjected to immunoblotting with antibody 4G10.
Colony Assay
Colony assay was performed as described by Yan et al. 26 Briefly, bone marrow cells from C57BL/6 mice were cultured with RPMI 1640 containing 15 U/mL interleukin (IL)-3. The cells were given PDGF-BB (20 ng/mL) alone or PDGF-BB plus either 20 g/mL of APA5 or APB5. After 5-day culture, the cells were counted and transferred to methylcellulose containing IL-3 (200 U/mL) and erythropoietin (2 U/mL). After 2-day culture, the number of colony formation units in culture was scored. In this assay, a colony (Ͼ40 cells) is composed primarily of granulocytes and/or macrophages.
Protocols for Feeding and Antibody Administration
To study advanced and early stages of atherogenesis, we designed 2 feeding protocols, protocol A and protocol B, respectively. As illustrated in Figure 1 , in protocol A, a total of 12 female apoEdeficient mice were switched to a high-fat diet containing 20% fat and 0.3% cholesterol (Oriental Yeast) at 6 weeks of age. In protocol B, a total of 11 mice were kept on CMF for the entire experimental period. In either protocol, 1 mg of APA5, APB5, or control rat IgG (purified by 50% ammonium sulfate precipitation) was administered intraperitoneally to each mouse on alternate days from 12 to 18 weeks. At the end of the experimental period, mice were killed by cervical dislocation and used for further analysis. All experimental protocols were performed in accordance with the guidelines of Kyoto University.
Tissue Preparation and Histochemistry
The tissue preparation was conducted as described previously. 3, 27 Briefly, the heart was removed from each mouse, snap-frozen in O.C.T. Compound (Sakura Finetek USA, Inc), and sequentially cut into a total of 36 cross sections (6 m thick each) around the aortic sinus. Of those sections, every third slice, ie, 12 samples per mouse, were subjected to staining either with oil red O (Sigma Chemical); with a biotin-labeled rat mAb, BM8, specific for mouse macrophage (BMA Biochemicals AG); or with a mouse mAb, 1A4, against smooth muscle ␣-actin labeled with a horseradish peroxidase/EPOS system (Dako). 3, 28 Each section was counterstained with Meyer's hematoxylin solution (Wako Pure Chemical Industries). For analysis of the intimal VSMC population, ␣-actin-positive cells were counted Feeding and antibody administration protocols. Protocols A and B were designed to study advanced and early stages of atherogenesis, respectively. In both protocols, mice were fed CMF from 4 to 6 weeks old. Protocol A, a total of 12 mice were transferred to a high-fat diet at 6 weeks old and fed until 18 weeks old. Protocol B, a total of 11 mice were kept on CMF from 6 to 18 weeks old. In either protocol, 1 mg APA5 or APB5 IP was administered to each mouse from 12 to 18 weeks old on alternate days. Four or 3 female mice were used in each injection experiment. For control experiments, an isotypematched irrelevant rat IgG was used.
in a total of 6 cross sections (every sixth section) from each mouse. To immunolabel with APA5 and APB5, aortic sinus sections from apoE-deficient mice fed a high-fat diet for 12 months were used. Each section was snap-frozen, treated with either APA5 or APB5, incubated with peroxidase-conjugated anti-rat IgG antibody, and reacted with TrueBlue Peroxidase Substrate (Kirkegaard Perry Laboratories), which stained blue. The sections were counterstained with nuclear fast red (Vector Laboratories), which stained the nucleus red.
Image Analysis and Quantification of Atherosclerotic Lesion
Atherosclerotic lesion size in each aortic section was evaluated for oil red O staining by Image-Pro Plus (Media Cybernetics). To estimate the severity of the lesions, we calculated the "plaque ratio" between the oil red O-stained area and the whole vessel area including the lumen, intima, media, and adventitia as described by Nicoletti et al. 29 For each animal, 12 sections, ie, every third section, were examined, and the mean of the fractional area was calculated and expressed as a percentage.
Statistical Analysis
Data are expressed as meanϮSD and were analyzed by ANOVA with Abacus Statview software (version 4.5). A value of PϽ0.05 was considered statistically significant.
Results
MAb APB5 Inhibited PDGFR-␤-Mediated Signal Pathway
We first examined whether mAb APB5 could block the PDGFR-␤-mediated signal pathway. When murine bone marrow cells were cultured with IL-3 and PDGF-BB, addition of APB5 suppressed proliferation of hematopoietic progenitors that are capable of forming a colony. In contrast, APA5, which has been shown to block the murine PDGFR-␣ pathway in vivo and in vitro, 19 had no suppressive effect ( Table 1) . We next studied whether the suppressive effect of APB5 was due to blockade of the signal transduction pathway through PDGFR-␤. As determined by immunoblot analysis with anti-phosphotyrosine and anti-PDGFR-␤ antibodies, phosphorylation of PDGFR-␤ in AC01 cells was completely inhibited (Figure 2, a, b, and c, lane 2) . In contrast, APA5 or irrelevant rat IgG had no inhibitory effect on phosphorylation (Figure 2, a and b, lanes 1, 3, and 4 ).
Intraperitoneal Administration of APB5 Prevented the Progression of Advanced Atherosclerotic Lesions in ApoE-Deficient Mice
We asked whether administration of anti-PDGFR mAbs could affect atherogenesis in apoE-deficient mice. For this purpose, we designed 2 feeding protocols, protocols A and B, to examine the effect of the antibodies on relatively advanced and early atherosclerotic lesions, respectively (Figure 1) . In protocol A, mice were fed a high-fat diet from 6 weeks of age so that the mice would develop fibroproliferative lesions by 18 weeks of age. 3, 18 The animals were subjected to antibody treatment as described in Methods. The mice that had been injected with irrelevant IgG developed advanced atherosclerotic lesions in the aortic root as determined by staining with oil red O (Figure 3a) . In contrast, the mice that received APB5 showed marked reduction of aortic lesion size ( Figure  3b ). The mice that had been given APA5 also showed a tendency toward reduction of lesion size, whereas the extent of the reduction was less than that seen in the mice injected with APB5 ( Figure 3c ). The plaque ratio in the mice injected with APB5 was as low as 33% of that in the control mice given irrelevant rat IgG, ie, 5.02Ϯ2.93% (nϭ4) and 15.12Ϯ4.62% (nϭ4), respectively (Pϭ0.0049). Although administration of APA5 slightly reduced the plaque ratio, by 28%, compared with that of the control mice, ie, 10.84Ϯ3.82% (nϭ4), there was no significant difference versus irrelevant rat IgG (Pϭ0.1501) ( Table 2 ). We next examined whether the antibodies could have a similar effect on the relatively early lesions. For this purpose, we designed protocol B, in which apoE-deficient mice were maintained on CMF from 6 to 18 weeks of age so that they would develop fatty streak lesions slowly in the aorta. 18 From 12 until 18 weeks of age, 1 mg of either APA5 or APB5 was administered on alternate days. As determined with oil red O, the mice given either antibody had tendency to show smaller lesions, whereas there was no significant difference in plaque ratios: the plaque ratios in the mice given APA5, APB5, and control rat IgG were 6.34Ϯ3.07% (nϭ4), 2.94Ϯ1.75% (nϭ4), and 7.83Ϯ2.32% (nϭ3), respectively (Pϭ0.07).
Administration of APB5 Markedly Prevented Accumulation of VSMCs in Atheromatous Lesions in ApoE-Deficient Mice
We further studied the effects of APB5 and APA5 on the cell composition in the atheromatous lesions. First, the aortic sections were stained with mAb 1A4 raised against ␣-actin to detect VSMCs. In the mice injected with irrelevant IgG or APA5, a large number of the cells immunolabeled by 1A4 were clustering in the intima and forming the fibrous cap structure overlying the subendothelial space 28 (Figure 4 , a, c, d, and f). We also counted the immunolabeled cells in the aortic intima. The numbers of stained cells in the examined sections from each mouse treated with irrelevant IgG and APA5 were 56.96Ϯ24.59 and 74.88Ϯ17.39, respectively ( Table 2 ). In striking contrast, the mice injected with APB5 presented a minimal number of such cells stained for ␣-actin in the intima, ie, 11.25Ϯ6.46 cells per mouse (PϽ0.001 versus irrelevant IgG or APA5) (Figure 4 , b and e) ( Table 2) . In these mice, most of the cells stained with anti-␣-actin were detected in the media. We next investigated the distribution of macrophages in the aorta sections by immunolabeling with the rat mAb BM8. The manner of distribution of macrophages did not differ in the subendothelial space in mice injected with either irrelevant IgG, APB5, or APA5 (Figure 4 , g, h, and i). Because it was suggested that VSMCs in the intima were more sensitive to the action of APB5, we investigated whether these cells were expressing PDGFR-␤ by immunohistochemical analysis, probing with APA5 and APB5. As shown in Figure 5 , when the aortic lesions of 12-month-old apoE-deficient mice that had been fed a highfat diet since 6 weeks of age were examined, the cells resident in the media and atheromatous plaque were immunolabeled either with APA5 ( Figure 5a ) or with APB5 ( Figure 5b) . In striking contrast, the cells in the intima were stained intensively with APB5 (indicated by arrow) (Figure 5b ) but minimally with APA5 (Figure 5a ).
Discussion
In this article, we examine the roles of PDGFR-␣ and PDGFR-␤ in atherogenesis in apoE-deficient mice. We previously reported that fatty streak formation was markedly suppressed in 12-week-old apoE-deficient mice by injection with AFS98, an antagonistic rat mAb against murine c-fms, whereas this antibody had minimal effect on the fibrous lesions with a large number of VSMCs. 3 On the basis of these observations, we attempted to seek the mechanism by which the fibrous lesions are formed We calculated the plaque ratio indicated by percent as described in Methods. The number of anti-smooth muscle ␣-actin-positive cells was counted in fibrous cap lesion. n indicates number of animals. Values are meanϮSD. *PϽ0.005 vs administration of control irrelevant IgG. †PϽ0.0001 vs administration of APB5. during this period. It is still poorly understood by which mechanism VSMCs accumulate in the intima during atherogenesis. Among numerous factors, PDGF has been known to be involved both in migration and in proliferation of the VSMCs. To test the hypothesis that PDGF is involved in formation of such fibrous lesions, we prepared a novel rat mAb APB5 raised against PDGFR-␤. The antagonistic effect of APB5 on the PDGFR-␤-mediated pathway was confirmed by its effects on colony formation of bone marrow cells (Table 1 ) and on PDGFR-␤ autophosphorylation (Figure 2 ). We previously demonstrated that APA5 blocks specifically PDGFR-␣ both in vivo and in vitro. 19 We confirmed specific binding of APA5 and APB5 to PDGFR-␣ and PDGFR-␤ by immunoblotting and immunoprecipitation (H.S. et al, unpublished observations). Furthermore, injection with APA5 and APB5 had distinctive effects on kidney development in neonate mice (H.S. et al, unpublished observations). These results demonstrate that APA5 and APB5 did selectively block the signal pathways mediated by PDGFR-␣ and PDGFR-␤, respectively. To examine the role of PDGF receptors in advanced and early lesions of atheroma, we designed 2 feeding protocols of apoE-deficient mice, protocols A and B, respectively ( Figure  1) . In protocol A, we found that administration of APB5 from 12 to 18 weeks of age was able to prevent the increase in the atherosclerotic lesion size as determined by oil red O staining ( Figure 3 ). As assessed quantitatively, the lesion size of the mice that had received APB5 was 33% of that of the control mice injected with irrelevant IgG. APA5 had much less effect. These results would imply that the PDGFR-␤-mediated signal transduction pathway plays a significant role in atherogenesis from 12 to 18 weeks of age, during which fibrous lesions are formed. In protocol B, we examined whether APA5 and APB5 could exert similar action, in which foam cell lesions are developed. APB5 showed a relatively weak tendency to reduce the size of the foam cell-rich lesion, but we could detect no significant difference from mice injected with APA5 or control IgG. Although this could be due to the limited number of mice examined and further study may be required, it was concluded that PDGFR-␤ would be more significantly involved in atherogenesis than PDGFR-␣ in apoE-deficient mice and that the blockade of PDGFR-␤mediated signal transduction could affect the development at least of advanced atherosclerotic lesions.
In the present study, what was most noteworthy was marked reduction of the density of intimal VSMCs in the mice injected with APB5 as determined by immunostaining with anti-␣-actin antibody 1A4 (Figure 4 , b and e) ( Table 2) . Because neither APA5 nor irrelevant rat IgG caused such a change in the distribution pattern of VSMCs in the arterial tissue (Figure 4, a, c, d , and f), these results would suggest that the preventive effect of APB5 on fibrous lesion formation is closely correlated to blockade of the signal transduction system mediated by PDGFR-␤. Interestingly, in the present study, the mice treated with APA5 showed larger numbers of 1A4-labeled cells in the aortic intima than did the irrelevant IgG-treated mice ( Table 2 ). Whether blockade of the PDGFR-␣ pathway could affect the change of intimal VSMC density must be investigated further.
Thus far, several studies have proposed a potential role of PDGF and its receptors on the development of intimal hyperplasia at sites of acute vascular injury. 10,30 -32 Although these results suggest that PDGF and its receptors might play important roles in the development of intimal lesions at sites of acute vascular injury, it has been unclear whether PDGF could be involved in the natural course of atherogenesis that proceeds without provocation, such as mechanical vascular injury. Our data have demonstrated for the first time that PDGFR-␤ is at least involved in the development of advanced atherosclerotic lesions. Because our present data indicate that inhibition of the PDGFR-␤ pathway suppressed fibrous lesion formation markedly in vivo, it must be determined by which mechanism the PDGFR-␤ pathway could be involved in the vessel wall. We are currently searching for the molecules that might be involved in signal transduction through either type of PDGFR in VSMCs.
In summary, we have developed a novel experimental system to investigate the behavior of VSMCs in the advanced lesion of atherosclerosis. In particular, we have shown that 2 types of PDGF receptor might have distinct regulatory roles in VSMCs and that the functional blockade of only PDGFR-␤ was effective enough to change the size and cell composition of the relatively advanced lesions. Whether the regulation or management of the number of VSMCs could have a therapeutic role in subjects with atheromatous lesions that are prone to erosion or thrombosis must be investigated further. Figure 5 . Photomicrograph of distribution of PDGFRs in aortic sinus from 12-month-old apoE-deficient mouse fed a high-fat diet. ApoE-deficient mice fed high-fat diet from 6 weeks of age were killed at 12 months of age. Serial sections of aortic root were immunostained with APA5 (a) and APB5 (b) as described in Methods. I indicates intima; M, media. and grants from the Research Fellowships of Japan Society for the Promotion of Science for Young Scientists.
